Ticagrelor (Brilinta)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a

History of changes in FDA indication

Note that this agent does not have a hematology-specific indication at this time.

  • 2011-07-20: Initial approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
  • 2015-09-03: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).

Also known as

  • Brand names: Brilinta, Brilique, Ticalog